United States of America
Carmine Stengone has more than 15 years of experience in the pharmaceutical and biotechnology industries, including positions in executive management, corporate development, finance, strategic planning, licensing, alliance management and venture funding. Mr. Stengone joined Avelas Biosciences in January 2012 as chief business officer and became chief executive officer and a member of the board of directors in January 2014. During his time with Avelas, Mr. Stengone has led all business activities, including securing a series B financing to drive AVB-620 into clinical development. In addition to his responsibilities with Avelas, Mr. Stengone serves as senior vice president, business development for COI Pharmaceuticals.